Research programme: small molecule therapeutics - Insilico Medicine/Westlake Pharma
Latest Information Update: 18 Aug 2021
At a glance
- Originator InSilico Medicine; Westlake Pharma
- Class Antivirals; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research COVID 2019 infections; Middle East respiratory syndrome coronavirus; Severe acute respiratory syndrome
Most Recent Events
- 02 Aug 2021 Insilico Medicine and Westlake Pharma entered an agreement to develop small molecule therapeutics
- 02 Aug 2021 Early research in COVID-2019 infections in China (unspecified route) prior to August 2021
- 02 Aug 2021 Early research in COVID-2019 infections in USA (unspecified route) prior to August 2021